STOCK MARKET BSE NSE

COVID-19: Bharat Biotech to launch Covaxin in 2021 second quarter

It said its immediate focus is to conduct the Phase 3 trials successfully across sites in the country.

Published: 01st November 2020 09:19 PM  |   Last Updated: 01st November 2020 09:19 PM   |  A+A-

'COVAXIN' was developed and manufactured at the company's Bio-safety Level-III high containment facility at Genome Valley.

'COVAXIN' was developed and manufactured at the company's Bio-safety Level-III high containment facility at Genome Valley.  (Photo| Special Arrangement)

By PTI

NEW DELHI: Bharat Biotech is planning to launch its vaccine for COVID-19 in the second quarter next year if it gets the requisite approvals from the Indian regulatory authorities, a top company official said.

It said its immediate focus is to conduct the Phase 3 trials successfully across sites in the country.

The company's vaccine candidate -Covaxin- has been developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV) using inactivated Sars-Cov-2, the virus that causes COVID-19.

The virus was isolated in an ICMR lab.

"If we get all the approvals after establishing strong experimental evidence and data, and efficacy and safety data in our last stage of trials, we aim to launch the vaccine in Q2 of 2021," Bharat Biotech International Executive Director Sai Prasad told PTI.

After the company received approval from the Drugs Controller General of India (DCGI) to conduct Phase 3 clinical trial to establish the efficacy of the vaccine candidate, it has begun site preparatory exercises for Phase 3, recruitment and dosage will begin in November, he added.

"The trial to be conducted in 25 to 30 sites across 13-14 states will provide two doses each for the vaccine and placebo recipients. About 2,000 subjects could be enrolled per hospital," Prasad said.

Asked about the investment on the vaccine, he said: "Our investment is about Rs 350-400 crore for the development of vaccine and the new manufacturing facilities, which include our investments for conducting the Phase 3 clinical trial, in the next six months".

On the company's plan to sell the vaccine to the government or to private players, Prasad said: "We are looking to supply for both government and private markets. We are also in preliminary discussions with other countries for probable supply."

Prasad said the price of the vaccine is yet to be determined, as the company is still looking at the cost of product development.

"Our immediate focus is to conduct Phase 3 trial successfully across sites," he added.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

IPL_2020
flipboard facebook twitter whatsapp